Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 9/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386736 | 1.00 | EED (0.41) | EEDTAAR1KDM4EGAAALDH1A1 | |
| SCHEMBL121801 | 0.85 | TAAR1 (0.43) | TAAR1KDM4EGAAALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29184016 | 0.82 | TAAR1 (0.41) | TAAR1KDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL11029574 | 0.82 | TAAR1 (0.41) | TAAR1KDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL27577860 | 0.82 | TAAR1 (0.39) | EEDTAAR1KDM4EGAAALDH1A1 | |
| SCHEMBL173876 | 0.82 | ALDH1A1 (0.36) | TAAR1ALDH1A1TSHR | |
| SCHEMBL7627111 | 0.79 | TAAR1 (0.45) | EEDTAAR1GAA | |
| SCHEMBL14144306 | 0.79 | EED (0.43) | EEDTAAR1KDM4EGAAALDH1A1 | |
| SCHEMBL15352403 | 0.79 | EED (0.40) | EEDTAAR1KDM4EGAAALDH1A1 | |
| SCHEMBL20558278 | 0.79 | EED (0.40) | EEDTAAR1KDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-3843728-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | NOVARTIS AG (CH) | 2025-02-18 | — | — | US | disclosed |
| EP-4471033-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-12037333-B2 | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037333-B2 | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4143187-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| WO-2014028591-A2 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2014-02-20 | — | — | WO | disclosed |
| CN-102070420-B | Method for preparing 2-bromo-6-fluorobenzaldehyde | UNIV CHANGZHOU | 2013-12-18 | — | — | CN | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| CN-102070420-A | Method for preparing 2-bromo-6-fluorobenzaldehyde | UNIV CHANGZHOU | 2011-05-25 | — | — | CN | disclosed |
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1474414-B1 | DIHYDRO-THIA-PHENANTHRENE-CARBONYL-GUANIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC REAGENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | EED 1267/4885TAAR1 4550/4885KDM4E 1439/4885 |
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | HIF1AN, HIF1A, EGLN2 | EED 1118/4885TAAR1 4767/4885KDM4E 1212/4885 |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | PTPN5, PTPN2, PTPRJ | EED 959/4885TAAR1 3755/4885KDM4E 1559/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | EED 1894/4885TAAR1 2209/4885KDM4E 394/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | EED 431/4885TAAR1 1238/4885KDM4E 1764/4885 |
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | EED 4013/4885TAAR1 853/4885KDM4E 4532/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | EED 1276/4885TAAR1 3288/4885KDM4E 2994/4885 |
| US-12037333-B2 | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication | PLPBP, EIF2AK2, TYMP | EED 2787/4885TAAR1 1640/4885KDM4E 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.